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The HMG-CoA reductase inhibitors (statins) are widely prescribed for patients with
hyperlipidemia and are generally well tolerated. Mild elevations in serum aminotransfer-
ases arise in up to 3% of treated patients, but clinically apparent drug-induced liver
injury is rare. The aim of this study is to report the presenting features and outcomes
of 22 patients with clinically apparent liver injury due to statins. Among 1,188 cases of
drug-induced liver injury enrolled between 2004 and 2012 in a prospective registry by
the U.S. Drug Induced Liver Injury Network, 22 were attributed to a statin. All patients
were evaluated in a standard fashion and followed for at least 6 months after onset. The
median age was 60 years (range 41-80), and 15 (68%) were female. The latency to onset
of liver injury ranged from 34 days to 10 years (median5 155 days). Median peak levels
were alanine aminotransferase 892 U/L, alkaline phosphatase 358 U/L, and total biliru-
bin 6.1 mg/dL. Nine patients presented with cholestatic hepatitis and 12 patients pre-
sented with hepatocellular injury, of which six had an autoimmune phenotype. Nine
patients were hospitalized, four developed evidence of hepatic failure, and one died. All
commonly used statins were implicated. Four patients developed chronic liver injury, of
which three had an autoimmune phenotype of liver injury. Conclusion: Drug-induced
liver injury from statins is rare and characterized by variable patterns of injury, a range
of latencies to onset, autoimmune features in some cases, and persistent or chronic
injury in 18% of patients, most of whom have an autoimmune phenotype. (HEPATOLOGY
2014;60:679-686)
T
he HMG-CoA reductase inhibitors (statins) are
among the most frequently prescribed medica-
tions worldwide, with over 143 million prescrip-
tions annually dispensed in the United States alone.1
Statins reduce cardiovascular morbidity and mortality in
high-risk patients with hyperlipidemia.2,3 They are also
generally well tolerated, although dose-dependent
adverse events, including myositis and myalgias, develop
in 10% to 15% of patients.4 In addition, up to 3% of
patients develop mild serum aminotransferase elevations
within the first year of therapy, but these elevations are
rarely associated with symptoms and often resolve even
with continued treatment.4,5
Clinically apparent drug-induced liver injury attrib-
uted to statins has been reported but appears to be
rare. A systematic review of the literature published in
2009 identified only 40 cases of statin hepatotoxicity,
mostly from single case reports and no case series with
more than four patients.6 The U.S. Acute Liver Failure
Study Group reported six cases of acute liver failure
attributed to statins among a total 131 cases of acute
liver failure due to drugs other than acetaminophen
over a 10-year period.7 In a 2-year, population-based
study from Iceland only three cases of liver injury
from statins were identified.8 In an analysis of 12 years
of adverse drug reaction reports to a Swedish registry,
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73 cases of liver injury attributed to statins were iden-
tified, 34% of which were jaundiced and 4% fatal.9
Although there is substantial literature on statin-
induced liver injury, the systematic evaluation and
exclusion of other liver diseases, details on dose and
duration of therapy, and long-term follow-up on
recovery are lacking.
The U.S. Drug Induced Liver Injury Network
(DILIN) is an ongoing multicenter, prospective study
of the etiologies and outcomes of liver injury due to
drugs, herbal medications, or dietary supplements in
the United States. In addition to carefully characteriz-
ing the presenting clinical features of liver injury due
to medications, DILIN collects biological samples for
mechanistic studies of pathogenesis.10,11 The current
study provides detailed information on the presenta-
tion and course of 22 cases of statin-induced liver
injury which underwent expert adjudication and stand-
ardized collection of clinical data, laboratory tests, and,
when available, liver biopsy findings.
Materials and Methods
The U.S. Drug-Induced Liver Injury Network
(DILIN). DILIN established a prospective registry in
September 2004 wherein patients were enrolled with
suspected liver injury due to any known drug, herbal,
or dietary supplement.10,11 Detailed descriptions of the
purpose and design of DILIN and its process of cau-
sality assessment have been published.10 Briefly, after
providing written informed consent, patients under-
went a medical history and physical examination,
including review of the dates, doses, and indications
for the suspect drug and other concomitant medica-
tions. Common causes of liver injury were excluded
such as viral hepatitis, alcohol, pancreatic, biliary, and
metabolic liver disease. All subjects had to meet prede-
fined laboratory entry criteria and were followed for at
least 6 months to help exclude other diagnoses. Testing
of stored specimens for acute hepatitis E virus infec-
tion was undertaken as previously described.12 Addi-
tionally, a Roussel Uclaf Causality Assessment Method
(RUCAM) score was assigned to each case.13 To be
included in the present analysis, the case had to be
adjudicated by expert opinion as definite (95%-100%
likelihood), very likely (75%-94% likelihood), or
probable (51%-74% likelihood). In cases where multi-
ple drugs were implicated, the statin had to have the
highest causality score. Each case was assigned a sever-
ity score of 1 to 5, in which 1 indicated serum enzyme
elevations without jaundice; 2, serum enzyme eleva-
tions and jaundice; 3, jaundice and hospitalization for
liver injury; 4, jaundice with signs of hepatic or other
organ failure; and 5, death from liver disease or liver
transplantation within 6 months of onset. Chronic
injury was defined as liver biochemical or histological
abnormalities that persisted for 6 months or more after
onset.10
Liver Histopathology. Available liver biopsies were
formally interpreted by the study pathologist (D.E.K.)
who was blinded to all clinical information. A full
description of the methods and scoring systems used
has recently been published.14 Features of autoimmune
liver injury were specifically sought, including interface
hepatitis, portal mononuclear cell infiltrates, plasma
cells, and focal necrosis.
Data Analysis. Standard descriptive statistics were
used to summarize the data including means and
standard deviations (SD), medians, and ranges for con-
tinuous variables, and frequencies and percentages for
categorical variables. Chi-square tests (or Fisher exact
test for situations with small frequencies) and nonpara-
metric tests were used to test the difference between
injury types for categorical and continuous variables,
respectively. P< 0.05 was considered statistically signif-
icant. All calculations were performed using SAS v. 9.2
(SAS Institute, Cary, NC).
Results
Demographics and Presenting Features. Between
September 2004 and November 2012, 1,188 patients
with suspected drug-induced liver injury were enrolled
into the DILIN prospective registry. Statins were
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initially implicated in 61 cases (6%), but upon formal
review only 22 were adjudicated as definitely (n5 2),
highly likely (n5 9), or probably (n5 11) attributable
to the statin (Fig. 1). In 15 of the 22 cases a statin
was the only implicated drug, whereas in the remain-
ing seven another drug(s) was also implicated but con-
sidered less likely as a cause. The 39 excluded cases
included 11 which were later found to be due to viral
hepatitis and 28 others in which the injury was judged
as unlikely or only possibly due to the statin, other
agents, or other diagnoses being considered more likely
(Supporting Table 1).
The 22 patients with statin-induced liver injury ranged
in age from 41 to 80 years (median5 60 years), 15
(68%) were women, and 18 (82%) were non-Hispanic
whites (Table 1). The average body mass index was 25
kg/m2 and seven (32%) patients had diabetes. One sub-
ject was known to have preexisting alcoholic liver disease
with portal hypertension and compensated cirrhosis, this
case being the only one with a fatal outcome.
Of the 22 patients, 19 presented with clinical symp-
toms and three were asymptomatic, the liver injury
being detected based upon routine liver tests. Fifteen
(68%) patients were jaundiced (total bilirubin 2.5
mg/dL) and four (18%) had elevations in serum inter-
national normalized ratio (INR) (>1.5). Fever was
reported by five subjects at presentation and rash in
four but these manifestations of immuno-allergic
injury were not prominent and no patient had a
peripheral eosinophil count of more than 500 cells/lL.
Eleven (50%) patients were reactive for at least one
autoantibody including antinuclear antibody (ANA) in
eight, smooth muscle antibody (SMA) in five, and
antimitochondrial antibody (AMA) in two cases, but
titers were usually modest and were 1:160 or greater
in only four patients.
The implicated statins included atorvastatin (n5 8),
simvastatin (n5 5), rosuvastatin (n5 4), fluvastatin
(n5 2), pravastatin (n5 2), and lovastatin (n5 1). The
daily dose was within the recommended range in all
patients and the median dose was 20 mg daily (Table 2).
The latency (time from starting statin to onset of liver
injury) varied widely. Using the time to initial identifica-
tion of abnormal liver tests as a definition, latency
ranged from 34 days to more than 10 years, with a
mean of 464 and a median of 155 days. The latency was
1 to 3 months in six (27%), 3 to 6 months in six (27%),
6 to 12 months in five (23%), and greater than a year in
the remaining five (23%). No patient developed drug-
induced liver injury within 4 weeks of starting the statin
(Table 2). Three patients had previous exposure to the
same statin, four were previously exposed to a different
statin, and two patients had a dose increase within a few
months of developing liver injury. Of the 17 cases with
available information on concomitant medications, 10
(59%) were taking three or more medications.
Hepatitis E (HEV) testing was available for 20
cases.12 Four (20%) cases had anti-HEV IgG, but
Fig. 1. Summary of U.S. DILIN expe-
rience in which statins were a suspect
drug.
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none of the four had IgM anti-HEV. HEV RNA test-
ing was only done on one of the four and was nega-
tive. Two patients with anti-HEV were tested
somewhat late in their course (5.3 and 9.5 months
after onset). In these two patients, IgG anti-HEV lev-
els did not change significantly over the next 6 months
(one increased slightly, one decreased slightly). All 22
cases were anti-HCV negative. Only 12 were tested for
HCV RNA and all were negative.
Phenotypes of Statin-Induced Liver Injury. The
clinical phenotype of liver injury also varied widely
but could be broadly categorized as either hepatocellu-
lar or cholestatic. For this categorization, the one fatal
case was excluded, because the clinical presentation
was with worsening jaundice and hepatic failure with
little change in serum enzyme elevations (acute-on-
chronic liver failure) and could not be categorized as
either cholestatic or hepatocellular. The remaining 21
cases included 12 that were hepatocellular and nine
cholestatic (Table 3). The categorization was based
usually on the initial ratio (R ratio) of serum alanine
aminotransferase (ALT) to alkaline phosphatase, both
expressed as multiples of the upper limit of the normal
range: those with an R >5 being hepatocellular and
those <2 being cholestatic. Two patients had an initial
R value between 2 and 5 and were thus “mixed,” but
R values subsequently decreased in both and both
Table 1. Clinical Features in 22 Cases of
Statin-Induced Liver Injury
Clinical Feature Median or Number Range
Age (years)* 60 41-80
Female sex 15 (68%)
White race 18 (82%)
BMI (kg/m2) 24 19-38
Onset <12 weeks 6 (27%)
Onset 12-24 weeks 6 (27%)
Onset >24 weeks 10 (45%)
Jaundice 15 (68%)
Itching 8 (36%)
Rash 4 (18%)
Fever (by history) 5 (23%)
Initial ALT (U/L)* 892 73-3074
Initial Alk P (U/L)* 338 79-1952
Initial R ratio 8.7 0.4-37
Initial bilirubin (mg/dL)* 3.9 0.3-18
Peak bilirubin (mg/dL)* 6.1 0.6-34
Peak INR (SD) 1.2 0.9-5.2
ANA (1:40) 8 (22%)
SMA (1:40) (n521) 8 (38%)
Severity score*
Mild (11) 7 (32%)
Moderate (21) 7 (32%)
Moderate hospitalized (31) 4 (18%)
Severe (41) 3 (14%)
Fatal (51) 1 (4%)
Liver transplant 0
Chronic injury at 6 months 4
*Median. BMI, body mass index; ALT, alanine aminotransferase; AST, aspar-
tate aminotransferase; Alk P, alkaline phosphatase; INR, international normal-
ized ratio.
Table 2. Selected Demographic, Lab, and Clinical Features of 22 Cases of Statin-Related Liver Injury
Case Statin Age Sex
DILIN
Causality Score
RUCAM
Score
Daily
Dose (mg)
Time to
Onset* (mo)
Peak
ALT (U/L)
Peak
Alk P (U/L)
Peak Bilirubin
(mg/dL) Pattern Outcome
Severity
Score
1 Atorvastatin 70 F 2 9 20 2.8 222 665 1.0 HC Resolved 1
2 Atorvastatin 65 F 1 9 80 4.1 666 861 1.0 HC Resolved 1
3 Atorvastatin 80 F 3 8 80 2.2 504 1952 18.8 Chol Resolved 4
4 Atorvastatin 54 M 2 7 40/80 5.2 [0.5] 502 200 5.2 Chol Resolved 2
5 Atorvastatin 71 M 3 8 10 41.6 3074 362 22.3 HC-AI-P Resolved 4
6 Atorvastatin 64 F 2 5 80 5.7 1490 529 4.2 HC Resolved 2
7 Atorvastatin 61 F 3 12 20/40 62.2 4560 512 30.2 HC-AI-P Resolved 4
8 Atorvastatin 78 F 2 8 10 120 1117 1006 17.0 Chol Resolved 3
9 Fluvastatin 77 F 3 7 80 37 1260 188 0.8 HC-AI Chronic 1
10 Fluvastatin 52 F 1 6 80 1.7 370 208 8.3 Chol Resolved 2
11 Lovastatin 80 F 3 5 50 5.1 177 724 20.2 Chol Resolved 2
12 Pravastatin 53 F 3 6 20 11.6 486 95 0.38 HC-AI Chronic 1
13 Pravastatin 50 M 2 8 20/40 7.2 [1] 2370 234 6.9 HC Resolved 2
14 Rosuvastatin 64 F 2 8 20 4.5 1119 399 1.3 HC Resolved 1
15 Rosuvastatin 59 F 3 8 10 25.8 275 526 3.5 Chol Chronic 3
16 Rosuvastatin 58 F 3 8 20 2.8 2583 184 16.4 HC-AI-P Chronic 3
17 Rosuvastatin 52 F 3 8 10 2.0 1506 235 1.7 HC Resolved 1
18 Simvastatin 67 M 3 6 40 5 145 142 33.5 AoC Died 5
19 Simvastatin 51 M 2 9 10 9.4 307 538 3.1 Chol Resolved 2
20 Simvastatin 41 F 2 6 20 7.5 1778 354 20.3 HC Resolved 2
21 Simvastatin 43 M 3 6 20 6.7 587 121 0.6 HC Resolved 1
22 Simvastatin 50 M 3 8 40 1.5 3336 348 20.9 HC-AI Resolved 3
*Time after dose increase given in brackets.
Abbreviations: see Table 1; HC, hepatocellular; Chol, cholestatic; AI, autoimmune features; P, treatment with prednisone.
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had jaundice and pruritus typical of cholestatic liver
injury.
RUCAM scores for the 22 cases ranged from 5 to
12 and comparison to DILIN causality scores showed
reasonable comparability (Supporting Table 2). All
cases were scored by RUCAM in the range considered
to be “highly probable” (9-12: n5 4) or “probable”
(6-8: n5 16) except for two cases that were scored by
RUCAM as “possible” (5: n5 2) but as probable
(Case #11) and highly likely (case #6) by expert opin-
ion (Table 1).
Comparisons of hepatocellular and cholestatic cases
of statin-induced liver injury showed that the hepato-
cellular cases tended to be younger (mean age 57 ver-
sus 65 years), but did not differ by type of statin,
distribution of latencies, gender, body mass index
(BMI), or disease severity (Table 3).
The 12 hepatocellular cases were further categorized
as having prominent autoimmune features or not.
Thus, 6 of the 12 had high levels of autoantibodies
(ANA or ASMA >1:80) or a liver biopsy suggesting
autoimmune hepatitis or both (Table 4). Comparisons
indicated that patients with autoimmune features were
more likely to develop evidence of chronic injury and
more likely to receive corticosteroids. Indeed, two cases
(Cases 7 and 16) of the six patients with the autoim-
mune phenotype still had evidence of active disease
more than 6 months after onset and received courses
of prednisone. Case 7 was treated with prednisone for
7 months and azathioprine was added 3 months after
starting the prednisone. The patient remained on aza-
thioprine 10 months after stopping atorvastatin. Case
16 was treated with prednisone and liver tests normal-
ized 5 months after stopping rosuvastatin and starting
prednisone. After 5 months, prednisone was stopped
and liver enzymes increased and prednisone was
restarted with persistent elevation in liver enzymes 2
months after restarting prednisone (7 months after
stopping rosuvastatin).
Details of the clinical history, laboratory results, and
outcome of representative examples of the different
phenotypes of statin-induced injury are given in the
Supporting Material, including cases of cholestatic
injury with or without complete resolution, hepato-
cellular injury with or without autoimmune features,
and with or without complete resolution. The single
fatal case of acute-on-chronic liver failure is also
described.
Table 3. Clinical Phenotypes in Statin-Associated Liver Injury
Clinical Feature
Hepatocellular
(n5 12)
Cholestatic
(n5 9) P Value
Age (years)* 57 (610.8) 65 (611.9) 0.12
Female sex 67% 78% 0.66
White race 75% 89% 0.47
BMI (kg/m2)* 26.1 (62.8) 23.7 (64.1) 0.18
Onset <12 weeks 12% 50% 0.27
Onset 12-24 weeks 25% 25%
Onset> 24 weeks 63% 25%
Jaundice 75% 56% 0.40
Itching 25% 44% 0.40
Rash 25% 11% 0.60
Initial ALT (U/L)† 1634 (486-3074) 307(177-1117) <0.001
Initial Alk P (U/L)† 228 (79-529) 665 (199-1952) 0.004
Initial R ratio† 19.2 (5.9-36.7) 1.6 (0.4-4.1) <0.001
Initial bilirubin (mg/dL)† 4.7 (0.3-18.4) 4.3 (0.4-12.2) 0.89
Peak bilirubin (mg/dL)† 5.6 (0.6-30.2) 5.2 (1.0-20.2) 0.94
Peak INR† 1.2 (0.9-1.6) 1.1 (1.0-2.7) 0.94
ANA 58% 11% 0.07
SMA‡ 45% 22% 0.37
Severity score † 3 (2-3) 2 (1-3) 0.78
Death§ 0% 0% 1.00
Liver transplant 0% 0% 1.00
Chronic injury at 6 months 25% 11% 0.63
Results given as proportions unless otherwise designated.
*Mean (standard deviation).
†Median, range.
‡For 8 subjects in each group.
§One fatal case (18) is not included in the table.
Abbreviations: see Table 1.
Table 4. Hepatocellular Phenotypes in
Statin-Associated Liver Injury
Clinical Features
Autoimmune
(n5 6)
Typical
(n5 6)
Age (years)* 62 (610.3) 53 (69.8)
Female sex 67% 67%
White race 66% 83%
BMI (kg/m2)* 27.9 (65.7) 24.3 (62.8)
Latency to onset
<12 weeks 33% 0
12-24 weeks 0% 25%
24-48 weeks 16% 75%
>1 year 50% 0
Jaundice 67% 83%
Itching 33% 17%
Rash 17% 33%
Fever 33% 17%
Initial ALT (U/L)† 2382 (486-3074) 1437 (587-2370)
Initial Alk P (U/L)† 240 (479-446) 274 (121-529)
Initial R ratio† 22.4 (15-37) 17.6 (5.9-23.4)
Initial bilirubin (mg/dL)† 7.8 (0.3-18.4) 2.8 (0.6-17.8)
Peak bilirubin (mg/dL)† 17.3 (0.6-30.2) 3.0 (0.7-20.3)
Peak INR† 1.3 (1.0-1.6) 1.1 (0.9-1.2)
ANA ( 1:40) 67% 50%
SMA ( 1:40) 67% 20%
Death 0% 0%
Liver transplant 0% 0%
Chronic injury at 6 months 50% 0%
Results given as proportions unless otherwise designated.
*Mean (standard deviation).
†Median (range).
None of the above differences were statistically significant.
Abbreviations: see Table 1.
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Histology. Eight subjects underwent liver biopsy.
Three subjects with cholestatic liver injury (Cases 3,
10, 19), three with hepatocellular-autoimmune (Cases
5, 7, 16), one patient with hepatocellular pattern only
(Case 17), and the fatal case of acute-on-chronic injury
(Case 18) underwent liver biopsy. Four liver biopsies
(Cases 3, 5, 10, and 16) showed cholestatic hepatitis,
with hepatocellular and canalicular cholestasis and bile
duct injury combined with portal and lobular inflam-
mation. Three cases (3, 5, and 16) had features sugges-
tive of autoimmune hepatitis with a moderate to
severe lymphocytic hepatitis with plasma cell (two had
serum autoantibodies). The remaining cases did not
have features suggestive of autoimmune hepatitis and
only Case 16 had increased numbers of eosinophils.
Confluent necrosis was seen in four cases and was the
dominant injury in case 17, in which clear zone 3
necrosis with inflammation was present. In the fatal
case (case 18), steatohepatitis with Mallory bodies,
microvesicular steatosis, and extensive perisinusoidal
fibrosis was also present along with the cholestasis. Ste-
atosis was a common finding (five of eight biopsies)
and probably represented preexisting fatty liver disease.
In two of the five cases with steatosis, there were many
cells with a foamy appearance consistent with microve-
sicular steatosis.
Discussion
The statins were originally thought to have a high
potential for causing drug-induced liver injury. When
first approved for use in the U.S., routine monitoring
of serum enzyme levels at monthly intervals was rec-
ommended. Subsequently, however, the frequency of
serum aminotransferase elevations during long-term
use of statins was found to be only slightly greater
than occurs with placebo treatments, and these abnor-
malities rarely resulted in clinically apparent liver
injury. In this prospective study of drug-induced liver
injury in the U.S., statins were initially implicated in
61 cases, but careful adjudication found only 22
(36%) could be considered convincing (more than
50% likelihood). All of the major statins were impli-
cated at rates similar to their relative use in the U.S.1
Perhaps the most striking finding in this study is the
lack of a single distinctive phenotype of liver injury
cause by statins. Both mild and severe, short and long
latency, and very cholestatic and very hepatocellular
cases were found and the clinical features did not cor-
relate with type of statin or conventional clinical dem-
ographics of patients. As with many other drugs,
hepatocellular injury was more common among
younger patients, but there was considerable overlap.
Time to onset, severity, and outcome did not seem to
correlate with any clinical phenotype or specific impli-
cated statin. For unclear reasons histology did not cor-
relate with biochemical classification; however, the
timing of the biopsy was often late in the course,
whereas the biochemical classification was usually
based on the laboratory findings at onset, and in addi-
tion many subjects did not have a biopsy.
A striking feature of some cases of statin-induced
liver injury was the prolonged latency. Indeed, 5 of the
22 patients had been taking the agent for a year or
more before onset of acute injury. This prolonged time
to onset is unusual, in that most cases of drug-induced
liver injury present within 6 months. Furthermore,
drugs typically associated with a long latency (nitrofur-
antoin, minocycline, or methyldopa) usually present
with a chronic hepatitis-like syndrome rather than an
acute hepatocellular or cholestatic hepatitis. Prolonged
latency was seen with most of the types of statins
(atorvastatin, simvastatin, fluvastatin, rosuvastatin)
presenting with both hepatocellular and cholestatic
patterns of liver injury. Although cases with long
latency are unusual, we systematically excluded other
causes of liver disease and liver test elevations resolved
with discontinuation of the statin. Cases of long
latency to onset of liver injury from statins have been
described before, but many case series lack any instan-
ces with a latency of above a year, perhaps because
such cases are excluded or considered less than prob-
ably related.6,9
A proportion of subjects with statin-associated liver
injury developed features of autoimmune hepatitis,
with ANA or SMA positivity, raised serum immuno-
globulin levels, and/or autoimmune hepatitis-like his-
tology. All cases had a hepatocellular pattern of injury
and a high proportion received systemic corticosteroid
therapy. Importantly, two of the six cases appeared to
have self-sustained autoimmune hepatitis with persis-
tently elevated serum enzymes that required immuno-
suppressive therapy when last seen, more than 6
months after initial onset. This pattern differs from
the autoimmune hepatitis-like injury that is associated
with minocycline and nitrofurantoin, which typically
resolves after the drug is discontinued, and in which
immunosuppressive therapy can ultimately be stopped.
One interpretation of these findings is that the liver
injury was coincidental and unrelated to the statin use,
which might not be unexpected given the frequency of
long-term statin use in the general population. On the
other hand, many of these cases did resolve once sta-
tins were discontinued and those that required long-
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term immunosuppressive therapy improved to a cer-
tain extent upon stopping the drug. Another interpre-
tation is that statins may trigger autoimmune hepatitis
in a susceptible patient, which may become self-
sustaining, if the statin was not stopped promptly or
the injury was particularly severe. Similar cases of self-
sustained autoimmune hepatitis seemingly triggered by
statin exposure have been reported.15,16 Importantly,
among the cases with hepatocellular injury without
serum autoantibodies in the current series, none devel-
oped chronic injury. Thus, the presence of autoanti-
bodies in patients with drug-induced liver from statins
may identify those at increased risk for chronic injury.
Although the clinical importance of chronic injury
from drugs is unknown, it seems prudent to recom-
mend that such subjects continue to be followed for
additional evidence of chronic liver disease.
While four of the 22 cases of statin-induced liver
injury were considered severe and one patient died,
the liver injury was largely mild-to-moderate in sever-
ity and self-limited in course. The one patient who
died had preexisting alcoholic cirrhosis and esophageal
varices and the other three cases that were scored as
severe had a transient prolongation of the prothrombin
time (INR >1.5) only, without hepatic encephalop-
athy, ascites, or fluid overload. The fatal case was adju-
dicated as probable3 because the underlying alcoholic
liver disease was thought to have contributed to his
death. Thus, statin-induced liver injury is usually
mild-to-moderate in severity and fairly rapidly reversed
in most cases once the agent is stopped.
The current results could not address the question
of whether there is crossreactivity among the different
statins in susceptibility to liver injury. One patient was
restarted on the same statin and rapidly redeveloped
acute injury. Four patients had received another statin
previously without hepatic injury, but none of the 22
patients in this series was switched to another statin
and monitored. In this regard, previous studies have
presented conflicting results, with most instances not
redeveloping hepatic injury when another statin was
started.9,17-21 However, because rare instances of recur-
rence of hepatotoxicity after switching to another sta-
tin have been reported, switching should be done with
caution and with careful monitoring.6,22
In summary, the current case series suggests that
clinically apparent liver injury from the statins is likely
a class effect and can arise many months and some-
times years after initiation. Statin-induced liver injury
has variable clinical presentations including distinctly
cholestatic, markedly hepatocellular, and even autoim-
mune hepatitis-like phenotypic manifestations. Liver
injury from statins is rare, usually mild-to-moderate in
severity, and rapidly reversed upon stopping, although
cases with an autoimmune phenotype of liver injury
were more likely to develop evidence of chronic injury.
Based on these data, prospective monitoring for drug-
induced liver injury from statins is not warranted, but
patients who develop a liver injury with an autoim-
mune phenotype should be closely monitored and
evaluated for immunosuppressive therapy if liver tests
fail to improve.
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